Literature DB >> 12604615

Aha1 binds to the middle domain of Hsp90, contributes to client protein activation, and stimulates the ATPase activity of the molecular chaperone.

Gregor P Lotz1, Hongying Lin, Anja Harst, Wolfgang M J Obermann.   

Abstract

The ATP-dependent molecular chaperone Hsp90 is an essential and abundant stress protein in the eukaryotic cytosol that cooperates with a cohort of cofactors/cochaperones to fulfill its cellular tasks. We have identified Aha1 (activator of Hsp90 ATPase) and its relative Hch1 (high copy Hsp90 suppressor) as binding partners of Hsp90 in Saccharomyces cerevisiae. By using genetic and biochemical approaches, the middle domain of Hsp90 (amino acids 272-617) was found to mediate the interaction with Aha1 and Hch1. Data base searches revealed that homologues of Aha1 are conserved from yeast to man, whereas Hch1 was found to be restricted to lower eukaryotes like S. cerevisiae and Candida albicans. In experiments with purified proteins, Aha1 but not Hch1 stimulated the intrinsic ATPase activity of Hsp90 5-fold. To establish their cellular role further, we deleted the genes encoding Aha1 and Hch1 in S. cerevisiae. In vivo experiments demonstrated that Aha1 and Hch1 contributed to efficient activation of the heterologous Hsp90 client protein v-Src. Moreover, Aha1 and Hch1 became crucial for cell viability under non-optimal growth conditions when Hsp90 levels are limiting. Thus, our results identify a novel type of cofactor involved in the regulation of the molecular chaperone Hsp90.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12604615     DOI: 10.1074/jbc.M212761200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  89 in total

1.  Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery.

Authors:  Philippe Meyer; Chrisostomos Prodromou; Chunyan Liao; Bin Hu; S Mark Roe; Cara K Vaughan; Ignacija Vlasic; Barry Panaretou; Peter W Piper; Laurence H Pearl
Journal:  EMBO J       Date:  2004-01-22       Impact factor: 11.598

2.  A cell-based screen for inhibitors of protein folding and degradation.

Authors:  Frank Boschelli; Jennifer M Golas; Roseann Petersen; Vincent Lau; Lei Chen; Diane Tkach; Qiang Zhao; Dave S Fruhling; Hao Liu; Chaneun Nam; Kim T Arndt
Journal:  Cell Stress Chaperones       Date:  2010-08-19       Impact factor: 3.667

Review 3.  Function of cytosolic chaperones in Tom70-mediated mitochondrial import.

Authors:  Anna C Y Fan; Jason C Young
Journal:  Protein Pept Lett       Date:  2011-02       Impact factor: 1.890

4.  Hsp90 cochaperone Aha1 is a negative regulator of the Saccharomyces MAL activator and acts early in the chaperone activation pathway.

Authors:  Fulai Ran; Nidhi Gadura; Corinne A Michels
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

5.  Effect of mutation of the tetratricopeptide repeat and asparatate-proline 2 domains of Sti1 on Hsp90 signaling and interaction in Saccharomyces cerevisiae.

Authors:  Gary Flom; Janae Weekes; Julia J Williams; Jill L Johnson
Journal:  Genetics       Date:  2005-10-11       Impact factor: 4.562

6.  Identification of novel quaternary domain interactions in the Hsp90 chaperone, GRP94.

Authors:  Feixia Chu; Jason C Maynard; Gabriela Chiosis; Christopher V Nicchitta; Alma L Burlingame
Journal:  Protein Sci       Date:  2006-06       Impact factor: 6.725

7.  The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth.

Authors:  Edward B Garon; Richard S Finn; Habib Hamidi; Judy Dering; Sharon Pitts; Naeimeh Kamranpour; Amrita J Desai; Wylie Hosmer; Susan Ide; Emin Avsar; Michael Rugaard Jensen; Cornelia Quadt; Manway Liu; Steven M Dubinett; Dennis J Slamon
Journal:  Mol Cancer Ther       Date:  2013-03-14       Impact factor: 6.261

Review 8.  Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.

Authors:  Alison Donnelly; Brian S J Blagg
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

9.  Diverging Novobiocin Anti-Cancer Activity from Neuroprotective Activity through Modification of the Amide Tail.

Authors:  Suman Ghosh; Yang Liu; Gaurav Garg; Mercy Anyika; Nolan T McPherson; Jiacheng Ma; Rick T Dobrowsky; Brian S J Blagg
Journal:  ACS Med Chem Lett       Date:  2016-07-05       Impact factor: 4.345

10.  Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors.

Authors:  Mehdi Mollapour; Dimitra Bourboulia; Kristin Beebe; Mark R Woodford; Sigrun Polier; Anthony Hoang; Raju Chelluri; Yu Li; Ailan Guo; Min-Jung Lee; Elham Fotooh-Abadi; Sahar Khan; Thomas Prince; Naoto Miyajima; Soichiro Yoshida; Shinji Tsutsumi; Wanping Xu; Barry Panaretou; William G Stetler-Stevenson; Gennady Bratslavsky; Jane B Trepel; Chrisostomos Prodromou; Len Neckers
Journal:  Mol Cell       Date:  2014-01-23       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.